Q-omics provides the consensus-scored MIR5008 profile across patient tissues and cancer cell-line models. MIR5008 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, MIR5008 is differentially expressed in 6, with the highest sampling consensus in ESCA. Additionally, MIR5008 RNA expression shows 9,500 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight CHOL, and ESCA as cancer lineages where MIR5008 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5008 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5008 survival associations across molecular data types. MIR5008 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5008 RNA expression–survival associations across cancer types. High MIR5008 expression shows unfavorable associations in CHOL, COAD, UCEC and MESO, but favorable associations in HNSC and PAAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify CHOL as the clearest survival context for MIR5008 RNA expression.
This table summarizes MIR5008 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5008. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5008 shows lower tumor expression in ESCA, BLCA, THCA, STAD and KIRP and higher tumor expression in BRCA. The ESCA box plot shows higher MIR5008 RNA expression in normal versus tumor tissue (log2 FC = −1.115, t-test p = .039).
This table shows molecular features associated with MIR5008 in patient tissues and cancer cell lines. In patient samples, MIR5008 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
